These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Younossi ZM Aliment Pharmacol Ther; 2008 Jul; 28(1):2-12. PubMed ID: 18410557 [TBL] [Abstract][Full Text] [Related]
14. [Non-alcoholic fatty liver disease--new view]. Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346 [TBL] [Abstract][Full Text] [Related]
15. Soy protein retards the progression of non-alcoholic steatohepatitis via improvement of insulin resistance and steatosis. Yang HY; Tzeng YH; Chai CY; Hsieh AT; Chen JR; Chang LS; Yang SS Nutrition; 2011 Sep; 27(9):943-8. PubMed ID: 21333494 [TBL] [Abstract][Full Text] [Related]
16. [Treatment of non-alcoholic steatohepatitis]. Fehér J; Hagymási K Orv Hetil; 2004 Mar; 145(12):631-4. PubMed ID: 15119118 [No Abstract] [Full Text] [Related]
17. [Diagnosis and therapy in NASH]. Tokushige K Rinsho Byori; 2009 Sep; 57(9):848-53. PubMed ID: 19860210 [TBL] [Abstract][Full Text] [Related]
18. [Common occurrence of non-alcoholic fatty liver disease and cholecystolithiasis]. Fraenkel E; Takács R; Hamvas J; Lengyel G; Fehér J Orv Hetil; 2007 Apr; 148(17):793-8. PubMed ID: 17452309 [TBL] [Abstract][Full Text] [Related]
19. [Non-alcoholic fatty liver disease in dyslipidemia and insulin resistance: similarities and differences; differential approach to therapy]. Lazebnik LB; Zvenigorodskaia LA; Egorova EG; Mel'nikova NV; Khomeriki SG Eksp Klin Gastroenterol; 2009; (8):4-11. PubMed ID: 20469672 [TBL] [Abstract][Full Text] [Related]
20. Non-alcoholic fatty liver disease in children. Janczyk W; Socha P Clin Res Hepatol Gastroenterol; 2012 Jun; 36(3):297-300. PubMed ID: 22521558 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]